Novo Nordisk CEO Mike Doustdar warned of near-term challenges in the company’s international operations as competition intensifies following the loss of market exclusivity in several key markets. Management cited planned generic and biosimilar launches in Europe and Asia that could pressure pricing and share. The CEO expects these headwinds to subtract roughly 2–3 percentage points from global volume growth next year, though U.S. and emerging markets are projected to offset much of the impact. Investors will be watching updates at the upcoming January investor day for revised guidance on international revenues and cost management initiatives.

In a preliminary safety update, the U.S. FDA reported that its review of adverse event reports and clinical trial data did not reveal evidence that GLP-1 receptor agonists, including Novo Nordisk’s Wegovy and Ozempic, cause suicidal thoughts or behavior. The agency noted limitations in many of the submitted reports—such as incomplete data and confounding factors—and observed similarly low event counts in both treatment and control arms of large outcome studies. While a minor risk cannot be definitively excluded, the FDA has launched a comprehensive meta-analysis of clinical trials and is tapping its Sentinel System database for post-marketing surveillance. The regulator reiterated that patients should not discontinue therapy without consulting a health care professional and will issue final recommendations when the review concludes.

Novo Nordisk’s share price jumped nearly 19% over the past month following FDA approval and commercial launch of the company’s oral GLP-1 formulation of semaglutide, branded as oral Wegovy, for obesity and cardiovascular risk reduction. This marks the first once-daily pill in the category, offering a significant convenience advantage over injectable alternatives. Analysts estimate peak annual sales of $8–10 billion for the oral variant alone, assuming it captures one-third of the U.S. obesity market by 2030. Management indicated that manufacturing capacity is on track to support global roll-out by mid-2026, with pricing set at a modest premium to existing injectable doses in key markets.